The FDA has approved the first drug specifically developed to treat postpartum depression; a new study links frequent and high-potency marijuana use to psychosis; and the Mississippi Senate has passed its heartbeat abortion ban.
The FDA approved Sage Therapeutics’ brexanolone (Zulresso), the first drug specifically developed to treat postpartum depression, reported The Associated Press. The intravenous drug, administered over 2.5 days, comes with an estimated price tag of $34,000 without insurance. A study assessing the drug found that when new mothers with moderate to severe depression took brexanolone, half stopped feeling depressed after 2.5 days, which was double the rate seen with those taking placebo.
As states around the country continue to take steps toward legalizing marijuana, a new study from The Lancet Psychiatry is warning of a health risk associated with frequent use: psychosis. According to the study, high frequency of daily marijuana use and high-potency marijuana increases the risk of a psychotic disorder, with daily marijuana users being 3.2 times more likely to have a psychotic disorder than never users and high potency users being 1.6 times more likely.
The Mississippi Senate passed its heartbeat abortion ban, which could bar abortion as early as 6 weeks into a women’s pregnancy. Fifteen Democrats voted against the bill. Governor Phil Bryant, R-Mississippi, has signaled that he will sign the legislation. If signed, the state will have the most restrictive abortion policy in the United States, although other states are debating similar legislation, reported Mississippi Today.
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Similar In-Hospital, Long-Term Survival Rates Found Among Male, Female Patients With AECOPD
March 18th 2024This study analyzed sex differences among patients with acute exacerbations of chronic obstructive pulmonary disease (AECOPD), with findings indicating that female smokers experience worse hospital outcomes despite similar overall survival rates.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
AstraZeneca joins efforts to address high drug prices by capping out-of-pocket costs for its inhalers; Opill, the first OTC birth control pill, is now accessible through online sales; expansion prompts questions on the effectiveness and regulation of remote monitoring technology.
Read More